| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/21/2011 | US20110091487 Melanoma biomarker and methods of uses |
| 04/21/2011 | US20110091486 Inhibition of post-radiation tumor growth |
| 04/21/2011 | US20110091485 Modulation of cell junctions |
| 04/21/2011 | US20110091483 Canine Anti-CD20 Antibodies |
| 04/21/2011 | US20110091482 Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis |
| 04/21/2011 | US20110091479 Novel anti-igf-ir antibodies and uses thereof |
| 04/21/2011 | US20110091477 Modulators of hepatocyte growth factor activator |
| 04/21/2011 | US20110091472 Compositions for treating psoriasis |
| 04/21/2011 | US20110091471 Treatment method for epithelial cancerous organism |
| 04/21/2011 | US20110091470 Anti-flt3 antibodies |
| 04/21/2011 | US20110091469 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 04/21/2011 | US20110091468 Connective tissue growth factor antibodies |
| 04/21/2011 | US20110091466 IgE ANTIBODIES FOR THE TREATMENT OF CANCER |
| 04/21/2011 | US20110091463 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 04/21/2011 | US20110091461 Binding domain-immunoglobulin fusion proteins |
| 04/21/2011 | US20110091460 Receptor-targeting reagents |
| 04/21/2011 | US20110091454 Methods and systems for annotating biomolecular sequences |
| 04/21/2011 | US20110091451 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 04/21/2011 | US20110091450 Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| 04/21/2011 | US20110091434 Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucosyltransferase |
| 04/21/2011 | US20110091419 Use of Pegylated IL-10 to Treat Cancer |
| 04/21/2011 | US20110091417 Interleukin-22 Polypeptides, Nucleic Acids Encoding The Same And Methods For The Treatment Of Pancreatic Disorders |
| 04/21/2011 | US20110091413 Therapeutic use of interleukin-2 mutants |
| 04/21/2011 | US20110091412 Mutant interleukin-2 (il-2) polypeptides |
| 04/21/2011 | US20110091410 Engineered CXCL12 Alpha Locked Dimer Polypeptide |
| 04/21/2011 | US20110091407 Polymer derived from linear polyethylenimine for gene transfer |
| 04/21/2011 | US20110091395 Extract of phaleria macrocarpa as an antineoplastic, anti-inflammatory and antiangiogenic agent |
| 04/21/2011 | US20110091390 Water soluble tetrapyrollic photosensitizers for photodynamic therapy |
| 04/21/2011 | US20110091384 Biomarker for identification of melanoma tumor cells |
| 04/21/2011 | US20110091383 Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents |
| 04/21/2011 | US20110091380 Chlorotoxins as drug carriers |
| 04/21/2011 | US20110091379 Method for treating tumors and their metastases |
| 04/21/2011 | US20110091377 Biomarkers for melanoma |
| 04/21/2011 | US20110091375 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| 04/21/2011 | US20110091372 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 04/21/2011 | DE102009049679A1 Pyrazolopyrimidinderivate Pyrazolopyrimidinderivate |
| 04/21/2011 | CA2814617A1 Novel mek inhibitors, useful in the treatment of diseases |
| 04/21/2011 | CA2777835A1 Supercoiled minicircle dna for gene therapy applications |
| 04/21/2011 | CA2777692A1 Isolation of a virus related to canine parvovirus-2 from a raccoon |
| 04/21/2011 | CA2777561A1 Combination |
| 04/21/2011 | CA2777546A1 Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors |
| 04/21/2011 | CA2777400A1 Granulysin in immunotherapy |
| 04/21/2011 | CA2777397A1 Polymeric systems for the delivery of anticancer agents |
| 04/21/2011 | CA2777283A1 Sulfoxide derivatives for the treatment of tumours |
| 04/21/2011 | CA2777250A1 Na-k pump modulation |
| 04/21/2011 | CA2777242A1 Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| 04/21/2011 | CA2777226A1 Cancer treatment |
| 04/21/2011 | CA2777043A1 Substituted piperidines that increase p53 activity and the uses thereof |
| 04/21/2011 | CA2776712A1 Use of il-17 receptor a antigen binding proteins |
| 04/21/2011 | CA2775959A1 Dual variable domain immunoglobulins and uses thereof |
| 04/21/2011 | CA2775266A1 Anti-cancer tamoxifen-melatonin hybrid ligand |
| 04/21/2011 | CA2774512A1 Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
| 04/20/2011 | EP2312024A1 Polymorphisms predictive of anthracycline-induced cardiotoxicity |
| 04/20/2011 | EP2311980A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/20/2011 | EP2311979A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
| 04/20/2011 | EP2311978A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/20/2011 | EP2311973A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 04/20/2011 | EP2311960A2 Bv8 nucleic acids and polypeptides with mitogenic activity |
| 04/20/2011 | EP2311956A1 Methods for making APO-2 ligand using divalent metal ions |
| 04/20/2011 | EP2311953A1 Bone/joint disease susceptibility gene and use thereof |
| 04/20/2011 | EP2311952A2 Antibodies to MRT-1 protein or fragments thereof |
| 04/20/2011 | EP2311951A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 04/20/2011 | EP2311950A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 04/20/2011 | EP2311946A1 Anti-system asc amino acid transporter 2 (asct2) antibody |
| 04/20/2011 | EP2311945A1 Bispecific antibodies substituting for functional proteins |
| 04/20/2011 | EP2311881A2 Cripto binding molecules |
| 04/20/2011 | EP2311880A2 Cripto binding molecules |
| 04/20/2011 | EP2311879A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 04/20/2011 | EP2311878A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 04/20/2011 | EP2311877A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 04/20/2011 | EP2311875A1 Treatment with anti-VEGF antibodies |
| 04/20/2011 | EP2311872A1 Albumin fusion proteins |
| 04/20/2011 | EP2311862A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311861A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311860A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311850A1 Anti-cancer cyclopenta[g]quinazoline compounds |
| 04/20/2011 | EP2311849A1 Specific binding agents of human angiopoietin-2 |
| 04/20/2011 | EP2311842A2 PI3K/M TOR inhibitors |
| 04/20/2011 | EP2311834A1 Crystal of thiazolidinedione compound, and process for production thereof |
| 04/20/2011 | EP2311829A1 Substituted alkylamine derivatives and methods of use |
| 04/20/2011 | EP2311825A1 Pyrimidineamines as angiogenesis modulators |
| 04/20/2011 | EP2311821A1 Polymorphic form of Imatinib mesylate and processes for its preparation |
| 04/20/2011 | EP2311818A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
| 04/20/2011 | EP2311814A1 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents |
| 04/20/2011 | EP2311809A1 Quinolinyloxyphenylsulfonamides |
| 04/20/2011 | EP2311808A1 Substituted alkylamine derivatives and methods of use |
| 04/20/2011 | EP2311799A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311798A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311797A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311796A1 4-dedimethylamino tetracycline compounds |
| 04/20/2011 | EP2311795A2 Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators |
| 04/20/2011 | EP2311495A1 Vascularization inhibitors |
| 04/20/2011 | EP2311494A1 Histone modification inhibitor specific to target gene |
| 04/20/2011 | EP2311493A1 Cytotoxic composition |
| 04/20/2011 | EP2311491A1 Composition comprising an antibody against macrophage colony-stimulating factor (M-CSF) and a chelating agent |
| 04/20/2011 | EP2311490A2 Uses of antibodies to aminophospholipids for cancer treatment |
| 04/20/2011 | EP2311476A2 Cancer cell growth inhibition by black bean (phaseolus vulgaris l) extracts |
| 04/20/2011 | EP2311470A1 Method for simultaneous induction of ctl and t cell |
| 04/20/2011 | EP2311461A1 Methods for treating cancer by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines |
| 04/20/2011 | EP2311455A1 Compounds for nonsense suppression, and methods for their use |